Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma

Leukemia

Volumn 29, Issue 2, 2015, Pages 448-455

  Satwani, P ^a   Jin, Z ^a   Martin, P L ^b   Bhatia, M ^a   Garvin, J H ^a   George, D ^a   Chaudhury, S ^c   Talano, J ^d   Morris, E ^e   Harrison, L ^e   Sosna, J ^a   Peterson, M ^b   Militano, O ^e   Foley, S ^e   Kurtzberg, J ^b   Cairo, M S ^e  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B LIPID COMPLEX; BUSULFAN; CARBOPLATIN; CARMUSTINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETOPOSIDE; FILGRASTIM; FLUCONAZOLE; FLUDARABINE; FOSCARNET; GANCICLOVIR; IFOSFAMIDE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; RITUXIMAB; SARGRAMOSTIM; TACROLIMUS; HLA ANTIGEN;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG DOSE SEQUENCE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; INFECTION PREVENTION; INTENTION TO TREAT ANALYSIS; LUNG ASPERGILLOSIS; MORTALITY; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; MYCOSIS; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PNEUMOCYSTOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; RELAPSE; SCHOOL CHILD; TREATMENT DURATION; YOUNG ADULT; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CLINICAL TRIAL; CYTOLOGY; DISEASE COURSE; FETUS BLOOD; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA, NON-HODGKIN; PROGNOSIS; RECURRENT DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FETAL BLOOD; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922470679     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.194     Document Type: Article

References (42)

1. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007; 109: 2736-2743.
2. Hochberg J, Waxman IM, Kelly KM, Morris E, Cairo MS. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol 2009; 144: 24-40.
3. Kelly KM, Sposto R, Hutchinson R, Massey V, McCarten K, Perkins S et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood 2011; 117: 2596-2603.
4. Cairo MS, Sposto R, Gerrard M, Auperin A, Goldman SC, Harrison L et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (>/= 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. J Clin Oncol 2012; 30: 387-393.
5. Daw S, Wynn R, Wallace H. Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents. Br J Haematol 2011; 152: 249-260.
6. Baker KS, Gordon BG, Gross TG, Abromowitch MA, Lyden ER, Lynch JC et al. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. J Clin Oncol 1999; 17: 825-831.
7. Johnston LJ, Horning SJ. Autologous hematopoietic cell transplantation in Hodgkin's disease. Biol Blood Marrow Transplant 2000; 6: 289-300.
8. Lieskovsky YE, Donaldson SS, Torres MA, Wong RM, Amylon MD, Link MP et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices. J Clin Oncol 2004; 22: 4532-4540.
9. Moskowitz AJ, Perales MA, Kewalramani T, Yahalom J, Castro-Malaspina H, Zhang Z et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 2009; 146: 158-163.
10. Schellong G, Dorffel W, Claviez A, Korholz D, Mann G, Scheel-Walter HG et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 2005; 23: 6181-6189.
11. Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, Dickerhoff R et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group. J Clin Oncol 2009; 27: 3363-3369.
12. Griffin TC, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009; 52: 177-181.
13. Harris RE, Termuhlen AM, Smith LM, Lynch J, Henry MM, Perkins SL et al. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962. Biol Blood Marrow Transplant 2011; 17: 249-258.
14. Miles RR, Arnold S, Cairo MS. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. Br J Haematol 2012; 156: 730-743.
15. Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007; 109: 2773-2780.
16. Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 1993; 11 : 2342-2350.
17. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versuslymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-653.
18. Mitterbauer M, Neumeister P, Kalhs P, Brugger S, Fischer G, Dieckmann K et al. Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma. Leukemia 2001; 15 : 635-641.
19. Peggs KS, Kayani I, Edwards N, Kottaridis P, Goldstone AH, Linch DC et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol 2011; 29 : 971-978.
20. Phillips GL, Reece DE, Barnett MJ, Connors JM, Fay JW, Herzig GP et al. Allogeneic marrow transplantation for refractory Hodgkin's disease. J Clin Oncol 1989; 7: 1039-1045.
21. Ratanatharathorn V, Uberti J, Karanes C, Abella E, Lum LG, Momin F et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050-1055.
22. Claviez A, Canals C, Dierickx D, Stein J, Badell I, Pession A et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 2060-2067.
23. Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010; 115: 3671-3677.
24. Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 3918-3924.
25. Waxman IM, Militano O, Baldinger L, Roman E, Qualter E, Morris E et al. Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning. Pediatr Transplant 2009; 13: 464-474.
26. Geyer MB, Jacobson JS, Freedman J, George D, Moore V, van de Ven C et al. A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. Br J Haematol 2011; 155: 218-234.
27. Satwani P, Jin Z, Duffy D, Morris E, Bhatia M, Garvin JH et al. Transplantationrelated mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients. Biol Blood Marrow Transplant 2013; 19: 552-561.
28. Bhatia M, Militano O, Jin Z, Figurski M, Shaw L, Moore V et al. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2010; 16: 333-343.
29. Osunkwo I, Bessmertny O, Harrison L, Cheung YK, Van de Ven C, del Toro G et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 2004; 10: 246-258.
30. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
31. Roman E, Osunkwo I, Militano O, Cooney E, van de Ven C, Cairo MS. Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation. Pediatr Blood Cancer 2008; 50: 325-330.
32. Shereck EB, Cooney E, van de Ven C, Della-Lotta P, Cairo MS. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients. Pediatr Blood Cancer 2007; 49: 306-312.
33. Bradley MB, Satwani P, Baldinger L, Morris E, van de Ven C, Del Toro G et al. Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases. Bone Marrow Transplant 2007; 40: 621-631.
34. Styczynski J, Tallamy B, Waxman I, van de Ven C, Milone MC, Shaw LM et al. A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents. Bone Marrow Transplant 2011; 46: 790-799.
35. Gross TG, Hale GA, He W, Camitta BM, Sanders JE, Cairo MS et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant 2010; 16: 223-230.
36. Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 2010; 116: 4934-4937.
37. Bradley MB, Cairo MS. Stem cell transplantation for pediatric lymphoma: past, present and future. Bone Marrow Transplant 2008; 41: 149-158.
38. Levine JE, Harris RE, Loberiza Jr. FR, Armitage JO, Vose JM, Van Besien K et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 2003; 101: 2476-2482.
39. Woessmann W, Peters C, Lenhard M, Burkhardt B, Sykora KW, Dilloo D et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents - a Berlin-Frankfurt-Munster group report. Br J Haematol 2006; 133: 176-182.
40. Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012; 97: 310-317.
41. Pulsipher MA, Boucher KM, Wall D, Frangoul H, Duval M, Goyal RK et al. Reducedintensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood 2009; 114: 1429-1436.
42. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812-1821.